Translational approaches for the prevention of estrogen receptor-negative breast cancer

European Journal of Cancer Prevention

Volumn 16, Issue 3, 2007, Pages 203-215

  Li, Yuxin ^a   Brown, Powel H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemoprevention; Estrogen receptor negative; Prevention

Indexed keywords

6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; ACETYLSALICYLIC ACID; AG 1487; ALITRETINOIN; ANASTROZOLE; AROMATASE INHIBITOR; BEXAROTENE; CANERTINIB; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ERLOTINIB; ESTROGEN RECEPTOR; EXEMESTANE; FENRETINIDE; GEFITINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IMATINIB; ISOTRETINOIN; LAPATINIB; LETROZOLE; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RALOXIFENE; RETINOID; RETINOL DERIVATIVE; ROFECOXIB; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; BONE DISEASE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE COURSE; DRUG MECHANISM; DRUG RESPONSE; ENDOMETRIUM CANCER; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPOTHYROIDISM; INTERSTITIAL LUNG DISEASE; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PIPERAZINES; PYRIMIDINES; RECEPTORS, CALCITRIOL; VITAMIN A;

EID: 34247148140     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e328011ed98     Document Type: Review

References (110)

1. Abe J, Nakano T, Nishii Y, Matsumoto T, Ogata E, Ikeda K. (1991). A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129:832-837.
2. Anzano MA, Byers SW, Smith JM, Peer CW, Mullen LT, Brown CC, et al. (1994). Prevention of breast cancer in the rat with 9-cis- retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 54:4614-4617.
3. Aoyama Y (2002). Experimental studies on the effects of the combined use of N-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen (TAM) for estrogen receptor (ER)-negative breast cancer. Kurume Med J 49:27-33.
4. Aranda A, Pascual A (2001). Nuclear hormone receptors and gene expression. Physiol Rev 81:1269-1304.
5. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131-2139.
6. Beatson G (1896). On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 148:101-107.
7. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. (2000). Non-lipid-related effects of statins. Ann Med 32:164-176.
8. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ. (2000). Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2:203-210.
9. de Bono JS, Rowinsky EK (2002). The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 8 (4 Suppl):S19-S26.
10. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. (2004). The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 100:2308-2316.
11. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. (1999). Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140:27-35.
12. Buchanan FG, Wang D, Bargiacchi F, DuBois RN (2003). Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278:35451-35457.
13. Buchwald H (1992). Cholesterol inhibition, cancer, and chemotherapy. Lancet 339:1154-1156.
14. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. (2001). Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125-134.
15. Cauley JA, Zmuda JM, Lui LY, Hillier TA, Ness RB, Stone KL, et al. (2003). Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 12:749-756.
16. Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG 3rd, et al. (2002). American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 20:3328-3343.
17. Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE, et al. (1999). Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 20:1905-1911.
18. Colston KW, Perks CM, Xie SP, Holly JM. (1998). Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 20:157-162.
19. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092.
20. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. (1999). The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197.
21. Cuzick J (2003). Aromatase inhibitors in prevention-data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163:96-103; discussion 264-266.
22. Cuzick J (2005). Aromatase inhibitors for breast cancer prevention. J Clin Oncol 23:1636-1643.
23. Cuzick J, Baum M (1985). Tamoxifen and contralateral breast cancer. Lancet 2:282.
24. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. (2002). First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817-824.
25. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. (2003). Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300.
26. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. (2005). Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23:254-266.
27. Davidson MH (2001). Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs 61:197-206.
28. Davies GL (2003). Cyclooxygenase-2 and chemoprevention of breast cancer. J Steroid Biochem Mol Biol 86:495-499.
29. Davies G, Martin LA, Sacks N, Dowsett M. (2002). Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 13:669-678.
30. Decensi A, Serrano D, Bonanni B, Cazzaniga M, Guerrieri-Gonzaga A. (2003). Breast cancer prevention trials using retinoids. J Mammary Gland Biol Neoplasia 8:19-30.
31. Dunn BK, Ford LG (2001). From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J 7:144-157.
32. Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, et al. (2002). Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer 94:2766-2792.
33. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. (1998). Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 95:8806-8811.
34. Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M, et al. (2002). Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 74:155-165.
35. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645.
36. Faggiotto A, Paoletti R (1999). State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension 34(4 Pt 2):987-996.
37. Falzon M (1997). The noncalcemic vitamin D analogues EB1089 and 22-oxacalcitriol interact with the vitamin D receptor and suppress parathyroid hormone-related peptide gene expression. Mol Cell Endocrinol 127: 99-108.
38. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. (1989). A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484.
39. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388.
40. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, et al. (2003). The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144: 5105-5117.
41. Glick AB, Flanders KC, Danielpour D, Yuspa SH, Sporn MB. (1989). Retinoic acid induces transforming growth factor-beta 2 in cultured keratinocytes and mouse epidermis. Cell Regul 1:87-97.
42. Goss PE, Strasser-Weippl K (2004). Prevention strategies with aromatase inhibitors. Clin Cancer Res 10(1 Pt 2):372S-379S.
43. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. (2003). A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793-1802.
44. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. (1996). Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 56:5566-5570.
45. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. (2002). Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62:1676-1681.
46. Harris CC, Sporn MB, Kaufman DG, Smith JM, Jackson FE, Saffiotti U. (1972). Histogenesis of squamous metaplasia in the hamster tracheal epithelium caused by vitamin A deficiency or benzo[a]pyrene-Ferric oxide. J Natl Cancer Inst 48:743-761.
47. Harris RE, Namboodiri KK, Farrar WB (1996). Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7:203-205.
48. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. (2000). Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60:2101-2103.
49. Herschman HR (1996). Prostaglandin synthase 2. Biochim Biophys Acta 1299:125-140.
50. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. (1990). Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323: 795-801.
51. Honig SF (2001). Tamoxifen for the reduction in the incidence of breast cancer in women at high risk for breast cancer. Ann N Y Acad Sci 949: 345-348.
52. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. (2001). Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8:97-114.
53. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, et al. (2002). Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 62:5405-5407.
54. Hussain EA, Mehta RR, Ray R, Das Gupta TK, Mehta RG. (2003). Efficacy and mechanism of action of 1alpha-hydroxy-24-ethyl-cholecalciferol (1alpha[OH]D5) in breast cancer prevention and therapy. Recent Results Cancer Res 164:393-411.
55. Hynes NE, Lane HA (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354.
56. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. (2005). Cancer statistics, 2005. CA Cancer J Clin 55:10-30.
57. Kirkpatrick K, Ogunkolade W, Elkak A, Bustin S, Jenkins P, Ghilchik M, et al. (2002). The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer. Curr Med Res Opin 18:237-241.
58. Kong G, Kim HT, Wu K, DeNardo D, Hilsenbeck SG, Xu XC, et al. (2005). The retinoid x receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res 65:3462-3469.
59. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. (1988). Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 318:1633-1637.
60. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. (2004). Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 79:935-945.
61. Lenferink AE, Simpson JF, Shawver LK, Coffey RJ, Forbes JT, Arteaga CL. (2000). Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. Proc Natl Acad Sci USA 97:9609-9614.
62. Lenzer J (2005). FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. BMJ 330:440.
63. Lerner LJ, Holthaus FJ Jr, Thompson CR (1958). A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p- methoxyphenyl ethanol. Endocrinology 63:295-318.
64. Lev DC, Kim SJ, Onn A, Stone V, Nam DH, Yazici S, et al. (2005). Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res 11: 306-314.
65. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, et al. (2001). Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563-18569.
66. Love-Schimenti CD, Gibson DF, Ratnam AV, Bikle DD. (1996). Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells. Cancer Res 56:2789-2794.
67. Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, et al. (2003). Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 95:1825-1833.
68. Mangelsdorf DJ, Evans RM (1995). The RXR heterodimers and orphan receptors. Cell 83:841-850.
69. Matsumoto H, Iino Y, Koibuchi Y, Andoh T, Horii Y, Takei H, et al. (1999). Antitumor effect of 22-oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice. Oncol Rep 6:349-352.
70. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, et al. (2001). Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142: 2776-2788.
71. Mehta RG, Williamson E, Patel MK, Koeffler HP. (2000). A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 92:418-423.
72. Mehta RG, Hussain EA, Mehta RR, Das Gupta TK. (2003). Chemoprevention of mammary carcinogenesis by 1alpha-hydroxyvitamin D5, a synthetic analog of Vitamin D. Mutat Res 523-524:253-264.
73. Meyskens FL Jr, Surwit E, Moon TE, Childers JM, Davis JR, Dorr RT, et al. (1994). Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst 86:539-543.
74. Moon RC, Grubbs CJ, Sporn MB (1976). Inhibition of 7,12-dimethylbenz(a) anthracene-induced mammary carcinogenesis by retinyl acetate. Cancer Res 36(7 Pt 2):2626-2630.
75. Moon RC, Thompson HJ, Becci PJ, Grubbs CJ, Gander RJ, Newton DL, et al. (1979). N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 39:1339-1346.
76. Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC. (1992). Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res 12:1147-1153.
77. Mueck AO, Seeger H, Wallwiener D (2003). Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause 10:332-336.
78. Mukherjee D, Nissen SE, Topol EJ (2001). Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954-959.
79. Nagaria NC, Cogswell J, Choe JK, Kasimis B. (2005). Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol 23:2423-2424.
80. Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, Watanabe K, et al. (2000). Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 91: 886-892.
81. Ng SS, Tsao MS, Nicklee T, Hedley DW. (2002). Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 1:777-783.
82. Oh Y, Gucev Z, Ng L, Muller HL, Rosenfeld RG. (1995). Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. Prog Growth Factor Res 6:503-512.
83. Pastorino U, Infante M, Maioli M, Chiesa G, Buyse M, Firket P, et al. (1993). Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11:1216-1222.
84. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. (1998). Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98-101.
85. Querfeld C, Rosen ST, Guitart J, Rademaker A, Fung BB, Posten W, et al. (2004). Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. J Am Acad Dermatol 51:25-32.
86. Rao GS, Murray S, Ethier SP (2000). Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 48:1519-1528.
87. Rendi MH, Suh N, Lamph WW, Krajewski S, Reed JC, Heyman RA, et al. (2004). The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. Cancer Res 64: 3566-3571.
88. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001-1009.
89. Seewaldt VL, Kim JH, Parker MB, Dietze EC, Srinivasan KV, Caldwell LE. (1999). Dysregulated expression of cyclin D1 in normal human mammary epithelial cells inhibits all-trans-retinoic acid-mediated G0/G1-phase arrest and differentiation in vitro. Exp Cell Res 249:70-85.
90. Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC. (2002). Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst 94:1301-1311.
91. Smith IE, Dowsett M (2003). Aromatase inhibitors in breast cancer. N Engl J Med 348:2431-2442.
92. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. (2000). COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89:2637-2645.
93. Spector NL, Xia W, Burris H, 3rd, Hurwitz H, Dees EC, Dowlati A, et al. (2005). Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23:2502-2512.
94. Sporn MB, Dunlop NM, Newton DL, Smith JM. (1976). Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332-1338.
95. Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, et al. (1999). A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 59:5671-5673.
96. Sun SY, Wan H, Yue P, Hong WK, Lotan R. (2000). Evidence that retinoic acid receptor beta induction by retinoids is important for tumor cell growth inhibition. J Biol Chem 275:17149-17153.
97. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, et al. (2003). Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 9:1566-1572.
98. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. (1998). Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352:93-97.
99. Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, et al. (1999). Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91: 1847-1856.
100. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA (2006);295:2727-2741.
101. Wakeling AE, Nicholson RI, Gee JM (2001). Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin Cancer Res 7(12 Suppl): 4350s-4355s; discussion 4411s-4412s.
102. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, et al. (2001). Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7:687-692.
103. Wolbach SB, Howe PR (1925). Tissue changes following deprivation of fat-soluble A vitamin. Proc Soc Exp Biol Med 77:753-777.
104. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. (2002). HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508-519.
105. Wu K, Kim HT, Rodriquez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, et al. (2000). 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40T antigen-transgenic mice. Clin Cancer Res 6:3696-3704.
106. Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, et al. (2002a). Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 11: 467-474.
107. Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, et al. (2002b). The retinoid Xreceptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 62:6376-6380.
108. Yang LM, Tin UC, Wu K, Brown P. (1999). Role of retinoid receptors in the prevention and treatment of breast cancer. J Mamm Gland Biol Neoplasia 4:377-388.
109. Yin F, Bruemmer D, Blaschke F, Hsueh WA, Law RE, Herle AJ. (2004). Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. Oncogene 23:4614-4623.
110. Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI. (2004). Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 58:344-352.